8-K Announcements
6Material company update
Apr 22, 2026·SEC
Material company update
Mar 30, 2026·SEC
Material company update
Feb 26, 2026·SEC
Boston Scientific Corporation(BSX)Earnings, Financials & Key Ratios
BSX•NYSE
23.2× P/E·Price updated Jun 17, 2026
AboutBoston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.Show more
- Revenue$20.07B+19.9%
- EBITDA$3.73B-4.4%
- Net Income$2.89B+55.7%
- EPS (Diluted)1.94+55.2%
- Gross Margin69.01%+12.6%
- EBITDA Margin18.6%-20.2%
- Operating Margin19.78%+25.7%
- Net Margin14.38%+29.9%
- ROE12.42%+39.1%
BSX Key Insights
Boston Scientific Corporation (BSX) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong Piotroski F-Score: 7/9
- ✓FCF machine: 18.2% free cash flow margin
- ✓High quality earnings: Operating CF exceeds net income
- ✓Strong 5Y sales CAGR of 15.2%
- ✓Healthy 5Y average net margin of 10.2%
✗Weaknesses
- ✗Weak momentum: RS Rating 9 (bottom 9%)
- ✗Trading more than 30% below 52-week high
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
Get notified when BSX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
BSX Price & Volume
Boston Scientific Corporation (BSX) stock price & volume — 10-year historical chart
Loading chart...
BSX Growth Metrics
Boston Scientific Corporation (BSX) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years10.38%
5 Years15.16%
3 Years16.54%
TTM19.88%
Profit CAGR
10 Years-
5 Years-
3 Years60.5%
TTM55.96%
EPS CAGR
10 Years-
5 Years-
3 Years63.25%
TTM54.82%
Return on Capital
10 Years8.19%
5 Years8.06%
3 Years8.97%
Last Year11.15%
BSX Recent Earnings
Boston Scientific Corporation (BSX) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 12/12 qtrs (100%)●Beat Revenue 12/12 qtrs (100%)
Q2 2026Latest
Apr 22, 2026Metric
Actual
Est
EPS
$0.80+1.5%
$0.79
Rev
$5.2B+0.6%
$5.2B
Q1 2026
Feb 4, 2026Metric
Actual
Est
EPS
$0.80+2.4%
$0.78
Rev
$5.3B+0.1%
$5.3B
Q4 2025
Oct 22, 2025Metric
Actual
Est
EPS
$0.75+5.0%
$0.71
Rev
$5.1B+1.9%
$5.0B
Q3 2025
Jul 23, 2025Metric
Actual
Est
EPS
$0.75+3.4%
$0.72
Rev
$5.1B+3.4%
$4.9B
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Apr 22, 2026 | $0.80vs $0.79+1.5% | $5.2Bvs $5.2B+0.6% |
| Q1 2026 | Feb 4, 2026 | $0.80vs $0.78+2.4% | $5.3Bvs $5.3B+0.1% |
| Q4 2025 | Oct 22, 2025 | $0.75vs $0.71+5.0% | $5.1Bvs $5.0B+1.9% |
| Q3 2025 | Jul 23, 2025 | $0.75vs $0.72+3.4% | $5.1Bvs $4.9B+3.4% |
Based on last 12 quarters of dataView full earnings history →
BSX Peer Comparison
Boston Scientific Corporation (BSX) competitors in Cardiovascular and heart rhythm devices — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 MDT | 100.32B | 78.14 | 21.65 | 3.62% | 13% | 9.49% | 0.59 | |
 EW | 49.97B | 86.68 | 47.37 | 11.55% | 17.64% | 10.35% | 0.07 | |
 SYK | 115.33B | 301.14 | 35.85 | 11.16% | 12.92% | 15.04% | 0.66 | |
 ZBH | 17.07B | 87.16 | 24.55 | 7.2% | 9.05% | 5.77% | 0.59 | |
 BDX | 51.3B | 141.61 | 24.29 | 8.23% | 5.33% | 4.54% | 0.76 | |
 BAX | 10.01B | 19.39 | -11.08 | 5.72% | -9.7% | -16.5% | 1.64 | |
 HOLX | 16.97B | 76.01 | 30.53 | 1.74% | 13.18% | 11.01% | 0.52 | |
 ABT | 153.82B | 88.46 | 11.58 | 4.59% | 31.88% | 27.26% | 0.32 |
Compare BSX vs Peers
Boston Scientific Corporation (BSX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
BSX Income Statement
Boston Scientific Corporation (BSX) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
Sales/Revenue | 9.05B | 9.82B | 10.73B | 9.91B | 11.89B | 12.68B | 14.24B | 16.75B | 20.07B |
Revenue Growth % | 7.89% | 8.57% | 9.28% | -7.66% | 19.92% | 6.68% | 12.29% | 17.61% | 19.87% |
Cost of Goods Sold | 3.18B | 3.35B | 3.86B | 4.34B | 4.43B | 4.97B | 5.41B | 6.48B | 6.22B |
COGS % of Revenue | 35.11% | 34.06% | 35.92% | 43.75% | 37.24% | 39.17% | 37.98% | 38.69% | 30.99% |
Gross Profit | 5.87B▲ 0% | 6.48B▲ 10.3% | 6.88B▲ 6.2% | 5.58B▼ 18.9% | 7.46B▲ 33.8% | 7.71B▲ 3.4% | 8.83B▲ 14.5% | 10.27B▲ 16.3% | 13.85B▲ 34.9% |
Gross Margin % | 64.89% | 65.94% | 64.08% | 56.25% | 62.76% | 60.83% | 62.02% | 61.31% | 69.01% |
Gross Profit Growth % | 9.88% | 10.32% | 6.21% | -18.94% | 33.81% | 3.39% | 14.48% | 16.26% | 34.93% |
Operating Expenses | 4.35B | 4.74B | 5.17B | 4.97B | 5.54B | 5.89B | 6.65B | 7.63B | 9.88B |
OpEx % of Revenue | 48.03% | 48.25% | 48.13% | 50.19% | 46.59% | 46.44% | 46.7% | 45.57% | 49.23% |
Selling, General & Admin | 3.28B | 3.56B | 3.93B | 3.79B | 4.29B | 4.52B | 5.19B | 5.98B | 6.89B |
SG&A % of Revenue | 36.26% | 36.21% | 36.59% | 38.2% | 36.05% | 35.64% | 36.45% | 35.73% | 34.31% |
Research & Development | 997M | 1.11B | 1.17B | 1.14B | 1.2B | 1.32B | 1.41B | 1.61B | 2.05B |
R&D % of Revenue | 11.02% | 11.33% | 10.94% | 11.53% | 10.13% | 10.43% | 9.93% | 9.64% | 10.22% |
Other Operating Expenses | 68M | 70M | 65M | 45M | 49M | 47M | 46M | 33M | 943M |
Operating Income | 1.52B▲ 0% | 1.74B▲ 13.9% | 1.71B▼ 1.4% | 601M▼ 64.9% | 1.92B▲ 219.8% | 1.82B▼ 5.1% | 2.18B▲ 19.6% | 2.63B▲ 20.8% | 3.97B▲ 50.7% |
Operating Margin % | 16.85% | 17.68% | 15.95% | 6.06% | 16.17% | 14.38% | 15.32% | 15.73% | 19.78% |
Operating Income Growth % | 23.38% | 13.9% | -1.44% | -64.89% | 219.8% | -5.1% | 19.57% | 20.82% | 50.7% |
EBITDA | 2.37B | 2.63B | 2.72B | 1.72B | 3.02B | 2.96B | 3.38B | 3.9B | 3.73B |
EBITDA Margin % | 26.18% | 26.78% | 25.36% | 17.38% | 25.36% | 23.34% | 23.71% | 23.31% | 18.6% |
EBITDA Growth % | 15.5% | 11.06% | 3.46% | -36.7% | 74.99% | -1.82% | 14.09% | 15.61% | -4.38% |
D&A (Non-Cash Add-back) | 844M | 894M | 1.01B | 1.12B | 1.09B | 1.14B | 1.2B | 1.27B | 0 |
EBIT | 1.16B | 1.69B | 1.2B | 389M | 1.43B | 1.6B | 2.26B | 2.67B | 3.73B |
Net Interest Income | -225M | -266M | -483M | -465M | -345M | -454M | -250M | -280M | -349M |
Interest Income | 5M | 3M | 30M | 3M | 4M | 10M | 22M | 107M | 0 |
Interest Expense | 230M | 269M | 513M | 468M | 349M | 464M | 272M | 387M | 349M |
Other Income/Expense | -592M | -315M | -1.02B | -680M | -846M | -683M | -196M | -353M | -586M |
Pretax Income | 933M▲ 0% | 1.42B▲ 52.4% | 687M▼ 51.7% | -79M▼ 111.5% | 1.08B▲ 1462.0% | 1.14B▲ 6.0% | 1.99B▲ 74.0% | 2.28B▲ 15.0% | 3.38B▲ 48.3% |
Pretax Margin % | 10.31% | 14.48% | 6.4% | -0.8% | 9.05% | 9% | 13.94% | 13.63% | 16.86% |
Income Tax | 828M | -249M | -4.01B | 2M | 36M | 443M | 393M | 436M | 493M |
Effective Tax Rate % | 88.75% | -17.51% | -584.13% | -2.53% | 3.35% | 38.83% | 19.8% | 19.11% | 14.56% |
Net Income | 104M▲ 0% | 1.67B▲ 1506.7% | 4.7B▲ 181.3% | -82M▼ 101.7% | 1.04B▲ 1368.3% | 698M▼ 32.9% | 1.59B▲ 128.2% | 1.85B▲ 16.4% | 2.89B▲ 55.7% |
Net Margin % | 1.15% | 17.01% | 43.78% | -0.83% | 8.75% | 5.5% | 11.19% | 11.07% | 14.38% |
Net Income Growth % | -70.03% | 1506.73% | 181.27% | -101.74% | 1368.29% | -32.88% | 128.22% | 16.38% | 55.66% |
Net Income (Continuing) | 104M | 1.67B | 4.7B | -81M | 1.04B | 698M | 1.59B | 1.85B | 2.89B |
Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 248M | 233M | 239M |
EPS (Diluted) | 0.07▲ 0% | 1.19▲ 1493.0% | 3.33▲ 180.0% | -0.08▼ 102.4% | 0.69▲ 946.1% | 0.45▼ 35.1% | 1.07▲ 140.6% | 1.25▲ 16.5% | 1.94▲ 55.2% |
EPS Growth % | -70.12% | 1493.04% | 179.99% | -102.44% | 946.06% | -35.09% | 140.59% | 16.52% | 55.2% |
EPS (Basic) | 0.08 | 1.21 | 3.38 | -0.08 | 0.69 | 0.45 | 1.08 | 1.26 | 1.96 |
Diluted Shares Outstanding | 1.39B | 1.4B | 1.41B | 1.42B | 1.43B | 1.44B | 1.46B | 1.49B | 1.49B |
Basic Shares Outstanding | 1.37B | 1.38B | 1.39B | 1.42B | 1.42B | 1.43B | 1.45B | 1.47B | 1.48B |
Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
BSX Balance Sheet
Boston Scientific Corporation (BSX) balance sheet — assets, liabilities & shareholders' equity
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
Total Current Assets | 3.82B | 4B | 4.7B | 6.69B | 6.32B | 5.76B | 6.51B | 6.92B | 8.79B |
Cash & Short-Term Investments | 188M | 146M | 217M | 1.73B | 1.93B | 928M | 865M | 414M | 2.04B |
Cash Only | 188M | 146M | 217M | 1.73B | 1.93B | 928M | 865M | 414M | 2.04B |
Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Accounts Receivable | 1.55B | 1.61B | 1.83B | 1.53B | 1.78B | 1.97B | 2.23B | 2.56B | 2.93B |
Days Sales Outstanding | 62.45 | 59.75 | 62.15 | 56.37 | 54.59 | 56.7 | 57.11 | 55.75 | 53.2 |
Inventory | 1.08B | 1.17B | 1.58B | 1.35B | 1.61B | 1.87B | 2.48B | 2.81B | 2.94B |
Days Inventory Outstanding | 123.85 | 127.19 | 149.46 | 113.7 | 132.74 | 137.17 | 167.62 | 158.28 | 172.73 |
Other Current Assets | 942M | 922M | 880M | 1.88B | 799M | 731M | 622M | 831M | 580M |
Total Non-Current Assets | 15.22B | 17B | 25.87B | 24.08B | 25.91B | 26.71B | 28.62B | 32.48B | 34.88B |
Property, Plant & Equipment | 1.7B | 1.78B | 2.42B | 2.54B | 2.69B | 2.83B | 3.3B | 3.74B | 4.5B |
Fixed Asset Turnover | 5.33x | 5.51x | 4.45x | 3.90x | 4.43x | 4.48x | 4.32x | 4.47x | 4.46x |
Goodwill | 7B | 7.91B | 10.18B | 9.95B | 11.99B | 12.92B | 14.39B | 17.09B | 18.28B |
Intangible Assets | 5.84B | 6.37B | 7.89B | 5.92B | 6.12B | 5.9B | 6B | 6.68B | 7.02B |
Long-Term Investments | -191M | -328M | 458M | 918M | 412M | 407M | 413M | 555M | 842M |
Other Non-Current Assets | 688M | 932M | 735M | 545M | 563M | 707M | 680M | 749M | 559M |
Total Assets | 19.04B▲ 0% | 21B▲ 10.3% | 30.57B▲ 45.6% | 30.78B▲ 0.7% | 32.23B▲ 4.7% | 32.47B▲ 0.7% | 35.14B▲ 8.2% | 39.4B▲ 12.1% | 43.67B▲ 10.9% |
Asset Turnover | 0.48x | 0.47x | 0.35x | 0.32x | 0.37x | 0.39x | 0.41x | 0.43x | 0.46x |
Asset Growth % | 5.22% | 10.28% | 45.56% | 0.7% | 4.72% | 0.74% | 8.21% | 12.12% | 10.86% |
Total Current Liabilities | 5.65B | 5.26B | 4.87B | 3.68B | 4.27B | 3.8B | 4.93B | 6.4B | 5.44B |
Accounts Payable | 530M | 349M | 542M | 513M | 794M | 862M | 942M | 960M | 1.14B |
Days Payables Outstanding | 60.89 | 38.07 | 51.3 | 43.17 | 65.46 | 63.33 | 63.57 | 54.07 | 67.12 |
Short-Term Debt | 1.8B | 2.25B | 1.42B | 13M | 261M | 20M | 531M | 1.78B | 389M |
Deferred Revenue (Current) | 191M | 328M | 144M | 138M | 208M | 220M | 266M | 306M | 313M |
Other Current Liabilities | 2.73B | 2.03B | 861M | 1.17B | 629M | 1.64B | 1.92B | 491M | 2.17B |
Current Ratio | 0.68x | 0.76x | 0.97x | 1.82x | 1.48x | 1.51x | 1.32x | 1.08x | 1.62x |
Quick Ratio | 0.49x | 0.54x | 0.64x | 1.45x | 1.10x | 1.02x | 0.82x | 0.64x | 1.08x |
Cash Conversion Cycle | 125.41 | 148.87 | 160.31 | 126.9 | 121.87 | 130.54 | 161.16 | 159.96 | 158.81 |
Total Non-Current Liabilities | 6.38B | 7.01B | 11.82B | 11.77B | 11.33B | 11.09B | 10.67B | 10.99B | 13.76B |
Long-Term Debt | 3.81B | 4.8B | 8.59B | 9.12B | 8.8B | 8.91B | 8.57B | 8.84B | 11.46B |
Capital Lease Obligations | 1M | 0 | 282M | 408M | 395M | 352M | 395M | 527M | 571M |
Deferred Tax Liabilities | 191M | 328M | 595M | 330M | 310M | 144M | 134M | 155M | 220M |
Other Non-Current Liabilities | 2.37B | 1.88B | 2.36B | 1.66B | 1.55B | 1.4B | 1.27B | 1.14B | 1.14B |
Total Liabilities | 12.03B | 12.27B | 16.69B | 15.45B | 15.61B | 14.9B | 15.61B | 17.39B | 19.2B |
Total Debt | 5.58B | 7.03B | 10.28B | 9.54B | 9.45B | 9.28B | 9.49B | 11.15B | 12.42B |
Net Debt | 5.39B | 6.88B | 10.06B | 7.8B | 7.53B | 8.35B | 8.63B | 10.73B | 10.37B |
Debt / Equity | 0.80x | 0.81x | 0.74x | 0.62x | 0.57x | 0.53x | 0.49x | 0.51x | 0.51x |
Debt / EBITDA | 2.35x | 2.67x | 3.78x | 5.54x | 3.13x | 3.14x | 2.81x | 2.86x | 3.33x |
Net Debt / EBITDA | 2.28x | 2.62x | 3.70x | 4.53x | 2.50x | 2.82x | 2.55x | 2.75x | 2.78x |
Interest Coverage | 5.06x | 6.29x | 2.34x | 0.83x | 4.08x | 3.46x | 8.30x | 6.90x | 10.70x |
Total Equity | 7.01B▲ 0% | 8.72B▲ 24.4% | 13.88B▲ 59.0% | 15.33B▲ 10.4% | 16.62B▲ 8.5% | 17.57B▲ 5.7% | 19.53B▲ 11.1% | 22B▲ 12.7% | 24.47B▲ 11.2% |
Equity Growth % | 4.13% | 24.45% | 59.05% | 10.45% | 8.46% | 5.72% | 11.13% | 12.66% | 11.22% |
Book Value per Share | 5.03 | 6.23 | 9.84 | 10.82 | 11.59 | 12.21 | 13.34 | 14.81 | 16.37 |
Total Shareholders' Equity | 7.01B | 8.72B | 13.88B | 15.33B | 16.62B | 17.57B | 19.28B | 21.77B | 24.23B |
Common Stock | 16M | 16M | 16M | 17M | 17M | 17M | 17M | 17M | 17M |
Retained Earnings | -8.39B | -6.95B | -2.25B | -2.38B | -1.39B | -750M | 819M | 2.67B | 5.57B |
Treasury Stock | -1.72B | -1.72B | -1.72B | -2.25B | -2.25B | -2.25B | -2.25B | -2.25B | -2.25B |
Accumulated OCI | -59M | 33M | 270M | 207M | 263M | 269M | 49M | 275M | -610M |
Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 248M | 233M | 239M |
BSX Cash Flow Statement
Boston Scientific Corporation (BSX) cash flow — operating, investing & free cash flow history
| Metric | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 |
|---|---|---|---|---|---|---|---|---|---|
Cash from Operations | 1.43B | 310M | 1.84B | 1.51B | 1.87B | 1.53B | 2.5B | 3.44B | 4.53B |
Operating CF Margin % | 15.76% | 3.16% | 17.1% | 15.21% | 15.74% | 12.03% | 17.58% | 20.51% | 22.59% |
Operating CF Growth % | 46.71% | -78.26% | 492.26% | -17.86% | 24.07% | -18.44% | 64.02% | 37.24% | 31.99% |
Net Income | 104M | 1.67B | 4.7B | -82M | 1.04B | 698M | 1.59B | 1.85B | 2.89B |
Depreciation & Amortization | 844M | 894M | 1.01B | 1.12B | 1.09B | 1.14B | 1.2B | 1.27B | 1.37B |
Stock-Based Compensation | 127M | 140M | 157M | 170M | 194M | 220M | 233M | 266M | 299M |
Deferred Taxes | 245M | -87M | -4.3B | -82M | -124M | -63M | -1M | 0 | 0 |
Other Non-Cash Items | 40M | -148M | 551M | 337M | 18M | 540M | 253M | 516M | 221M |
Working Capital Changes | 66M | -2.16B | -282M | 42M | -351M | -1B | -770M | -462M | -246M |
Change in Receivables | -30M | -110M | -130M | 335M | -279M | -220M | -238M | -351M | -269M |
Change in Inventory | -107M | -83M | -290M | -65M | -346M | -321M | -660M | -228M | -188M |
Change in Payables | 195M | -710M | 111M | 88M | 408M | -255M | 118M | 243M | 296M |
Cash from Investing | -1.01B | -1.92B | -5.04B | -411M | -1.6B | -2.01B | -2.57B | -5.69B | -2.64B |
Capital Expenditures | -319M | -316M | -461M | -376M | -554M | -612M | -711M | -790M | -876M |
CapEx % of Revenue | 3.53% | 3.22% | 4.29% | 3.79% | 4.66% | 4.83% | 4.99% | 4.72% | 4.36% |
Acquisitions | -560M | -1.45B | -4.29B | 12M | -1.43B | -1.54B | -1.81B | -4.64B | -1.59B |
Investments | - | - | - | - | - | - | - | - | - |
Other Investing | -131M | 1M | 1M | 87M | -1M | 106M | -52M | -257M | -171M |
Cash from Financing | 110M | 1.43B | 2.97B | 293M | -95M | -548M | 5M | 1.81B | -395M |
Debt Issued (Net) | 123M | 1.41B | 2.79B | -999M | 0 | -165M | -4M | 1.83B | -491M |
Equity Issued (Net) | 85M | 101M | 123M | 1.42B | 110M | 136M | 182M | 230M | 282M |
Dividends Paid | 0 | 0 | 0 | -28M | -55M | -55M | -28M | 0 | 0 |
Share Repurchases | 0 | 0 | 0 | -535M | 0 | 136M | 0 | 0 | 0 |
Other Financing | -98M | -74M | 56M | -95M | -150M | -464M | -145M | -243M | -186M |
Net Change in Cash | 530M▲ 0% | -190M▼ 135.8% | -222M▼ 16.8% | 1.39B▲ 725.2% | 171M▼ 87.7% | -1.04B▼ 709.4% | -82M▲ 92.1% | -449M▼ 447.6% | 1.54B▲ 443.2% |
Free Cash Flow | 1.11B▲ 0% | -6M▼ 100.5% | 1.38B▲ 23016.7% | 1.13B▼ 17.7% | 1.32B▲ 16.3% | 914M▼ 30.5% | 1.7B▲ 86.3% | 2.65B▲ 55.3% | 3.66B▲ 38.3% |
FCF Margin % | 12.23% | -0.06% | 12.81% | 11.42% | 11.07% | 7.21% | 11.96% | 15.79% | 18.22% |
FCF Growth % | 85.74% | -100.54% | 23016.67% | -17.67% | 16.25% | -30.55% | 86.32% | 55.31% | 38.3% |
FCF per Share | 0.79 | -0.00 | 0.97 | 0.80 | 0.92 | 0.63 | 1.16 | 1.78 | 2.45 |
FCF Conversion (FCF/Net Income) | 13.71x | 0.19x | 0.39x | -18.39x | 1.80x | 2.19x | 1.57x | 1.85x | 1.57x |
Interest Paid | 0 | 262M | 449M | 359M | 338M | 450M | 259M | 250M | 0 |
Taxes Paid | 0 | 1.04B | 242M | 207M | 302M | 662M | 512M | 656M | 0 |
BSX Key Ratios
Boston Scientific Corporation (BSX) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | 5.32% | 1.51% | 21.24% | 41.59% | -0.56% | 6.51% | 4.08% | 8.59% | 8.93% | 12.42% |
Return on Invested Capital (ROIC) | 7.82% | 9.37% | 9.3% | 6.49% | 1.92% | 6.1% | 5.46% | 6.05% | 6.49% | 8.81% |
Gross Margin | 63.71% | 64.89% | 65.94% | 64.08% | 56.25% | 62.76% | 60.83% | 62.02% | 61.31% | 69.01% |
Net Margin | 4.14% | 1.15% | 17.01% | 43.78% | -0.83% | 8.75% | 5.5% | 11.19% | 11.07% | 14.38% |
Debt / Equity | 0.81x | 0.80x | 0.81x | 0.74x | 0.62x | 0.57x | 0.53x | 0.49x | 0.51x | 0.51x |
Interest Coverage | 1.76x | 5.06x | 6.29x | 2.34x | 0.83x | 4.08x | 3.46x | 8.30x | 6.90x | 10.70x |
FCF Conversion | 2.80x | 13.71x | 0.19x | 0.39x | -18.39x | 1.80x | 2.19x | 1.57x | 1.85x | 1.57x |
Revenue Growth | 12.16% | 7.89% | 8.57% | 9.28% | -7.66% | 19.92% | 6.68% | 12.29% | 17.61% | 19.87% |
Related:BSX Dividend History·BSX Revenue History·BSX Price History·BSX P/E History·BSX Financial Ratios·BSX Institutional Holders
BSX SEC Filings & Documents
Boston Scientific Corporation (BSX) SEC filings — annual & quarterly reports (10-K, 10-Q)
BSX Frequently Asked Questions
Boston Scientific Corporation (BSX) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Boston Scientific Corporation (BSX) reported $20.07B in revenue for fiscal year 2025. This represents a 1273% increase from $1.46B in 1996.
Boston Scientific Corporation (BSX) grew revenue by 19.9% over the past year. This is strong growth.
Yes, Boston Scientific Corporation (BSX) is profitable, generating $2.89B in net income for fiscal year 2025 (14.4% net margin).
Dividend & Returns
Boston Scientific Corporation (BSX) has a return on equity (ROE) of 12.4%. This is reasonable for most industries.
Boston Scientific Corporation (BSX) generated $3.63B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.